Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Are Potential Biosimilar Sponsors Still Hesitant About The Pathway Despite Expected Growth?

Executive Summary

IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.

You may also be interested in...

Private Equity Reinvents Its Take On Biopharma

Biopharma offers the best PE returns of any health care sector, but represents only about a third of private equity investment in health care as investors remain wary of high-risk R&D and tend to focus on easier targets, which are in limited supply. As the low-hanging fruit disappears, PE investors are looking at new approaches beyond outright purchases and sorting out opportunities in emerging markets.

GPhA Tactics In Fight Against Calif. Biosimilar Bill Draw FDA Attention

The trade group stopped disseminating an advertisement opposing notification legislation because the agency said it could create confusion about FDA’s stance; GPhA continues to oppose the California measure, which faces an Oct. 13 deadline for the governor’s signature or veto.

FDA, Trying To Build Trust In Biosimilars, Turns To Generics Strategy

GPhA and other opponents of a California prescriber notification bill say an FDA statement on the standards for interchangeability supports their view; statement’s language that efforts to undermine public confidence in biosimilars are “worrisome” mirrors remarks made by FDA Commissioner Hamburg at a GPhA meeting.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts